Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial-Reference-Cited by-同舟云学术

Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial

Published:2008-04-08 Issue:8 Volume:100 Page:542-551
ISSN:0027-8874
Container-title:JNCI Journal of the National Cancer Institute
language:en
Short-container-title:JNCI Journal of the National Cancer Institute

Author:

von Minckwitz G.,Kummel S.,Vogel P.,Hanusch C.,Eidtmann H.,Hilfrich J.,Gerber B.,Huober J.,Costa S. D.,Jackisch C.,Loibl S.,Mehta K.,Kaufmann M.,

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/100/8/542/7683518/djn085.pdf

Reference17 articles.

1. Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update

2. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27

3. Dose-Dense Doxorubicin, Docetaxel, and Granulocyte Colony-Stimulating Factor Support With or Without Tamoxifen as Preoperative Therapy in Patients With Operable Carcinoma of the Breast: A Randomized, Controlled, Open Phase IIb Study

4. Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis

5. Capecitabine/Taxane Combination Therapy: Evolving Clinical Utility in Breast Cancer

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into “ARness”;Cell Reports Medicine;2024-06

2. Oncoproteomics by 3D MALDI with MRI-PET Imaging in Cancer;Pharmacoproteomics;2024

3. Association between event-free survival and overall survival in early-stage triple-negative breast cancer;Future Oncology;2023-08-21

4. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer;Breast Cancer Research and Treatment;2023-04-15

5. Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy;npj Breast Cancer;2023-04-07